Rodent Models - CNS Disorders

Request information or ask a question about pharmacological models for Alzheimer’s Disease

• Transgenic mice models (APP/PS1 double, Tg2576+, presenilin knockout)
• A-beta infusion model in mice and rats
• Aged models (mice, rats, rhesuses monkeys)
• Fimbria-Fornix models

Many CROs offer studies on aged animals as well as transgenic and induced models to test putative new Alzheimer’s disease (AD) therapies, and neurodegeneration and neurodegenerative treatments. Expected therapeutic endpoints can be measured by behavioral tests, immunohistochemistry assays, biochemical analysis, and MRI.

Alzheimer’s Disease is a progressive neurodegenerative disorder characterized by loss and structural alteration of nerve cells and deposition of spots of a proteinaceous material (“amyloid plaques”), which result in memory loss and impairment judgment, decision making, orientation to physical surroundings, and language.

In vivo models of Alzheimer’s Disease are an important part of the pathway for developing new treatments. Mice and rats models are practical for analysis of metabolism and distribution of lead compounds and its effects on amyloid plaque deposition in the brain, while canine and primate models provide assessment of cognitive dysfunction syndrome development with phenotypes closely resembling the human condition.